SP-0146: Oligometastatic disease: Radiophysics implementation and pitfalls
نویسندگان
چکیده
منابع مشابه
Stereotactic Ablative Radiotherapy for Oligometastatic Disease in Liver
Liver metastasis in solid tumors, including colorectal cancer, is the most frequent and lethal complication. The development of systemic therapy has led to prolonged survival. However, in selected patients with a finite number of discrete lesions in liver, defined as oligometastatic state, additional local therapies such as surgical resection, radiofrequency ablation, cryotherapy, and radiother...
متن کاملStereotactic Body Radiotherapy in the Management of Oligometastatic Disease.
BACKGROUND The treatment of oligometastatic disease has become common as imaging techniques have advanced and the management of systemic disease has improved. Use of highly targeted, hypofractionated regimens of stereotactic body radiotherapy (SBRT) is now a primary management option for patients with oligometastatic disease. METHODS The properties of SBRT are summarized and the results of re...
متن کاملOligometastatic Disease in Colorectal Cancer - How to Proceed?
BACKGROUND Oligometastatic disease in colorectal cancer may affect the liver, lung, and peritoneum. This review mainly focuses on colorectal liver metastases (CRLM) and highlights recommendations and therapeutic strategies drawn from the current literature and consensus conferences. The following data address a paradigm shift in surgical approaches to CRLM, pushing the limits of multimodal trea...
متن کاملOligometastatic Disease in the Peritoneal Space with Gastrointestinal Cancer.
OBJECTIVES Treatment options for patients with gastrointestinal cancer and oligometastastic disease remain the domain of the medical oncologist. However, in selected cases, attempts to remove or destroy the tumor burden seem appropriate. BACKGROUND DATA During the last decade, the treatment of localized and isolated tumor nodules, such as lung, liver or peritoneal metastasis, has changed. Pre...
متن کاملOligometastatic Disease in Pancreatic Cancer - How to Proceed?
BACKGROUND Pancreatic cancer is a highly aggressive malignancy and will become the second leading cause of cancer-related death in the USA and also in Germany by 2030. Furthermore, the majority of patients with pancreatic ductal adenocarcinoma (PDAC) will present with distant metastases, limiting surgical management in this population as there is little evidence available to support surgical or...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Radiotherapy and Oncology
سال: 2017
ISSN: 0167-8140
DOI: 10.1016/s0167-8140(17)30589-3